Effect of pioglitazone on serum uric acid levels in newly diagnosed, drug-naïve patients with type 2 diabetes

Endocrine Research

Volumn 38, Issue 3, 2013, Pages 151-159

  Kutoh, Eiji ^a,b   Hori, Tadataka ^a  

^a Biomedical Center   (Japan)

^b Gyoda General Hospital   (Japan)

Author keywords

Beta cell function; Insulin resistance; Pioglitazone; Type 2 diabetes; Uric acid

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN; PIOGLITAZONE; URIC ACID;

ADULT; ARTICLE; BODY MASS; CLINICAL ASSESSMENT; CONTROLLED STUDY; DRUG EFFECT; GLUCOSE BLOOD LEVEL; HOMEOSTASIS MODEL ASSESSMENT BETA; HOMEOSTASIS MODEL ASSESSMENT R; HUMAN; MAJOR CLINICAL STUDY; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; URIC ACID BLOOD LEVEL;

EID: 84879510526     PISSN: 07435800     EISSN: None     Source Type: Journal    
DOI: 10.3109/07435800.2012.745128     Document Type: Article

References (25)

1. Feig DI, Kang D-H, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med 2008;359(17):1811-1821
2. Cardona F, Rojo-Martínez G, de la Cruz Almaraz M, Soriguer F, García-Fuentes E, Tinahones FJ. Uric acid predicts type 2 diabetes mellitus in the general population. Endocrinol Nutr 2009;56(2):66-70
3. Kodama S, Saito K, Yachi Y, et al. The association between serum uric acid and development of type 2 diabetes mellitus. A Meta-Analysis. Diabetes Care 2009;32(9):1737-1742
4. Kramer CK, von Mühlen D, Jassal SK, Barrett-Connor E. Serum uric acid levels improve prediction of incident type 2 diabetes in individuals with impaired fasting glucose: The Rancho Bernardo Study. Diabetes Care 2009;32(7):1272-1273
5. Meriden T. Progress with thiazolidinediones in the management of type 2 diabetes mellitus. Clin Ther 2004;26(2):177-190 (Pubitemid 38339010)
6. Furnsinn C, Waldhausl W. Thiazolidinediones: Metabolic actions in vitro. Diabetologia 2002;45 (9):1211-1223
7. Fujiwara T, Horikoshi H. Troglitazone and related compounds: Therapeutic potential beyond diabetes. Life Sci 2000;67(20):2405-2416
8. Evans RM, Barish GD, Wang YX. PPARs and the complex journey to obesity. Nat Med 2004;10 (4):355-361 (Pubitemid 38508511)
9. Campbell IW. Long-Term glycemic control with pioglitazone in patients with type 2 diabetes. Int J Clin Pract 2004;58(2):192-200 (Pubitemid 38425750)
10. Dormandy JA, Charbonnel B, Eckland DJ, et al. PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): A randomised controlled trial. Lancet 2005;366(9493):1279-1289 (Pubitemid 41416583)
11. Tominaga M. Diagnostic criteria for diabetes mellitus. Rinsho Byori 1999;47(10):901-908
12. Ma Y, Olendzki BC, Merriam PA, et al. A randomized clinical trial comparing low-glycemic index versus ADA dietary education among individuals with type 2 diabetes. Nutrition 2008;24(1):45-56 (Pubitemid 350216377)
13. Tominaga M, Makino H, Yoshino G, et al. Japanese standard reference material JDS Lot 2 for haemoglobin A1c. II: Present state of standardization of haemoglobin A1c in Japan using the new reference material in routine clinical assays. Ann Clin Biochem 2005;42(Pt 1):47-50 (Pubitemid 40209065)
14. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28(7):412-419 (Pubitemid 15018832)
15. Gotfredsen A, McNair P, Christiansen C, Transbol I. Renal hypouricaemia in insulin treated diabetes mellitus. Clin Chim Acta 1982;120(3):355-361 (Pubitemid 12141127)
16. Cook DG, Shaper AG, Thelle DS, Whitehead TP. Serum uric acid, serum glucose and diabetes: Relationships in a population study. Postgrad Med J 1986;62(733):1001-1006 (Pubitemid 17181719)
17. Facchini F, Chen YD, Hollenbeck CB, Reaven GM. Relationship between resistance to insulinmediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration. JAMA 1991;266:3008-3011
18. Riches PL, Wright AF, Ralston SH. Recent insights into the pathogenesis of hyperuricaemia and gout. Hum Mol Genet 2009;18(R2):R177-R184
19. Ames BN, Cathcart R, Schwiers E, Hochstein P. Uric acid provides an antioxidant defense in humans against oxidant-And radical-caused aging and cancer: A hypothesis. Proc Natl Acad Sci USA 1981;78(11):6858-6862 (Pubitemid 12216861)
20. Becker BF. Towards the physiological function of uric acid. Free Radic Biol Med 1993;14(6):615-631 (Pubitemid 23172569)
21. Patterson RA, Horsley ET, Leake DS. Prooxidant and antioxidant properties of human serum ultrafiltrates toward LDL: Important role of uric acid. J Lipid Res 2003;44(3):512-521 (Pubitemid 37279698)
22. So A, Thorens B. Uric acid transport and disease. J Clin Invest 2010;120(6):1791-1799
23. Kutoh E, Ukai Y. Alogliptin as an initial therapy in patients with newly diagnosed, drug naïve type 2 diabetes: A randomized, control trial. Endocrine 2012;41(3):435-441
24. Nissen SE. The rise and fall of rosiglitazone. Eur Heart J 2010;31(7):773-776
25. Bakker SJ, Gans RO, ter Maaten JC, Teerlink T, Westerhoff HV, Heine RJ. The potential role of adenosine in the pathophysiology of the insulin resistance syndrome. Atherosclerosis 2001;155(2):283-290 (Pubitemid 32209297)